4-溴邻苯二甲酰亚胺 | 6941-75-9

• 物质功能分类: 化学试剂 - 有机试剂 - 酰亚胺
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 中文名称: 4-溴邻苯二甲酰亚胺
• 中文别名: 5-溴异吲哚-1,3-二酮；4-溴酞酰亚胺
• 英文名称: 5-Bromoisoindoline-1,3-dione
• 英文别名: 4-bromophthalimide；5-bromoisoindole-1,3-dione；5-bromophthalimide；5-bromopthalamide；5-bromo-1,3-dihydro-1,3-dioxo-2H-isoindole
• CAS: 6941-75-9
• 化学式: C₈H₄BrNO₂
• mdl: MFCD00466049
• 分子量: 226.029
• InChiKey: GNYICZVGHULCHE-UHFFFAOYSA-N

物化性质

• 熔点：
  235 °C
• 密度：
  1.826±0.06 g/cm3(Predicted)
• 溶解度：
  几乎全溶于N,N-DMF溶液中。

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  46.2
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 安全说明：
  S26,S36/37/39
• 海关编码：
  2925190090
• 危险类别码：
  R36/37/38
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  存放于室温环境中，并请密封保存。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
4-Bromophthalimide
Product Name:
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
4-Bromophthalimide
Ingredient name:
CAS number: 6941-75-9

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C8H4BrNO2
Molecular weight: 226.0

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

化学性质：黄色至浅黄色粉末

反应信息

• 作为反应物：
  描述：

  4-溴邻苯二甲酰亚胺 在 ammonium hydroxide 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 20.0h， 生成 4-溴邻苯二甲腈
  参考文献：
  名称：

  四（二乙基膦基）-，四（乙基苯基膦基）-和四（二苯基膦基氧化物）-取代酞菁

  摘要：

  四（膦酸二乙酯），四（苯基次膦酸乙酯）和四（二苯基膦氧化物）取代的酞菁

  DOI：

  10.1002/hlca.200490081
• 作为产物：
  描述：

  4-溴邻苯二甲酸 在 硫氰酸铵 作用下， 反应 0.17h， 以84%的产率得到4-溴邻苯二甲酰亚胺
  参考文献：
  名称：

  四（二乙基膦基）-，四（乙基苯基膦基）-和四（二苯基膦基氧化物）-取代酞菁

  摘要：

  四（膦酸二乙酯），四（苯基次膦酸乙酯）和四（二苯基膦氧化物）取代的酞菁

  DOI：

  10.1002/hlca.200490081
• 作为试剂：
  描述：

  1,3-dioxoisoindolin-2-yl (tert-butoxycarbonyl)valinate 在 4-溴邻苯二甲酰亚胺 、 4-(三氟甲基)苯硫酚 、 caesium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 6.0h， 以76%的产率得到tert-butyl (1-(5-bromo-1,3-dioxoisoindolin-2-yl)-2-methylpropyl)carbamate
  参考文献：
  名称：

  N-（乙酰氧基）邻苯二甲酰亚胺的硫酚催化可见光光氧化还原脱羧偶联

  摘要：

  我们已经开发了在不添加光催化剂的情况下N-（乙酰氧基）邻苯二甲酰亚胺的可见光光氧化还原脱羧偶合，其中简单的和可商购的苯酚被用作有效的有机催化剂，而4-（三氟甲基）苯硫酚显示出最佳的催化活性。选择了三个代表性的脱羧实例，包括一个氨基化和两个C–C键偶联，以确认可见光氧化还原反应的功效，结果表明它们在室温下表现良好。有趣的发现应该为有机分子的可见光光氧化还原转化提供一种新颖且环保的策略。

  DOI：

  10.1021/acs.orglett.6b03300

文献信息

• Certain pyrazoline derivatives with kinase inhibitory activity
  申请人：Adams Ruth S.

  公开号：US20080171754A1

  公开（公告）日：2008-07-17

  The present invention provides certain pyrazoline compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutical compositions and methods of using the compositions in the treatment of various diseases.

  本发明提供了某些吡唑啉化合物，可用作蛋白激酶的抑制剂。该发明还提供了药物组合物和使用这些组合物治疗各种疾病的方法。
• CHEMICAL COMPOUNDS
  申请人：Deng Jianghe

  公开号：US20090143372A1

  公开（公告）日：2009-06-04

  The invention is directed to novel indole carboxamide derivatives. Specifically, the invention is directed to compounds according to formula I: where R1, R2, R3, U and V are defined below and to pharmaceutically acceptable salts thereof. The compounds of the invention are inhibitors of IKK2 and can be useful in the treatment of disorders associated with inappropriate IKK2 (also known as IKKβ) activity, such as rheumatoid arthritis, asthma, and COPD (chronic obstructive pulmonary disease). Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting IKK2 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

  这项发明涉及新型吲哚羧酰胺衍生物。具体而言，该发明涉及符合以下式I的化合物： 其中R1、R2、R3、U和V如下定义，并且其药学上可接受的盐。该发明的化合物是IKK2的抑制剂，可用于治疗与不当IKK2（也称为IKKβ）活性相关的疾病，如类风湿性关节炎、哮喘和慢性阻塞性肺病（COPD）。因此，该发明进一步涉及包含该发明化合物的药物组合物。该发明还进一步涉及使用该发明化合物或包含该发明化合物的药物组合物抑制IKK2活性和治疗相关疾病的方法。
• Multicyclic bis-amide MMP inhibitors
  申请人：Powers Timothy

  公开号：US20060173183A1

  公开（公告）日：2006-08-03

  The present invention relates generally to bis-amide group containing pharmaceutical agents, and in particular, to multicyclic bis-amide MMP-13 inhibitor compounds. More particularly, the present invention provides a new class of MMP-13 inhibiting compounds, containing a pyrimidinyl bis-amide group in combination with a heterocyclic moiety, that exhibit an increased potency and solubility in relation to currently known bis-amide group containing MMP-13 inhibitors.

  本发明总体涉及含有双酰胺基团的药物制剂，特别是多环双酰胺MMP-13抑制剂化合物。更具体地，本发明提供了一类新型的MMP-13抑制化合物，它们含有与杂环部分结合的嘧啶基双酰胺基团，与目前已知含双酰胺基团的MMP-13抑制剂相比，显示出增加的活性和溶解度。
• [EN] MODULATORS OF THE HISTAMINE H3 RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO<br/>[FR] MODULATEURS DU RÉCEPTEUR D'HISTAMINE H3 UTILES POUR LE TRAITEMENT D'AFFECTIONS QUI LUI SONT ASSOCIÉES
  申请人：ARENA PHARM INC

  公开号：WO2009105206A1

  公开（公告）日：2009-08-27

  Amide derivatives of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the histamine H3 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of histamine H3-associated disorders, such as cognitive disorders, epilepsy, brain trauma, depression, obesity, disorders of sleep and wakefulness such as excessive daytime sleepiness, narcolepsy, shift-work sleep disorder, drowsiness as a side effect from a medication, maintenance of vigilance to aid in the completion of tasks and the like, cataplexy, hypersomnia, somnolence syndrome, jet lag, sleep apnea and the like, attention deficit hyperactivity disorder (ADHD), schizophrenia, allergies, allergic responses in the upper airway, allergic rhinitis, nasal congestion, dementia, Alzheimer's disease, pain and the like.

  Formula (Ia)的酰胺衍生物及其药物组合物，可调节组胺H3受体的活性。本发明的化合物及其药物组合物用于治疗组胺H3相关疾病的方法，如认知障碍、癫痫、脑外伤、抑郁症、肥胖症、睡眠和觉醒障碍（如白天过度嗜睡、嗜睡症、倒班工作睡眠障碍、药物副作用引起的嗜睡、保持警觉以帮助完成任务等）、猝倒、嗜睡症、嗜睡综合征、时差反应、睡眠呼吸暂停等、注意力缺陷多动障碍（ADHD）、精神分裂症、过敏、上呼吸道过敏反应、过敏性鼻炎、鼻塞、痴呆症、阿尔茨海默病、疼痛等。
• The Art of Filling Protein Pockets Efficiently with Octahedral Metal Complexes
  作者：Sebastian Blanck、Jasna Maksimoska、Julia Baumeister、Klaus Harms、Ronen Marmorstein、Eric Meggers

  DOI：10.1002/anie.201108865

  日期：2012.5.21

  Better fit, less effort: An easy‐to‐synthesize ruthenium phthalimide complex (tan‐colored carbon atoms in the picture) was designed to bind within the active site of the p21‐activated kinase 1 in a novel fashion that differs from that of the previously established staurosporine‐inspired metallopyridocarbazoles (gray‐colored carbon atoms).

  更合适，更省力：一种易于合成的邻苯二甲酰亚胺钌复合物（图中棕褐色碳原子）被设计为以一种不同于 p21 活化激酶 1 的活性位点的新方式结合先前建立的受星形孢菌素启发的金属吡啶并咔唑（灰色碳原子）。

表征谱图